ArticleCentral-European journal of immunology2025
Curcumin modulates inflammatory responses in peripheral blood mononuclear cells from women with gestational diabetes mellitus.
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Curcumin is a multi-functional component with anti-inflammatory and immunomodulatory properties. Unregulated immune responses may be a causative factor in the development of gestational diabetes mellitus (GDM). This study investigated the effect and mechanisms of curcumin on regulatory T cells/Th17 axis, and secretion of related cytokines (interleukin [IL]-17A, IL-6, and IL-10) in peripheral blood mononuclear cells (PBMCs) of healthy women and women with GDM. Material and methods: This research involved in vitro experiments to evaluate the influence of curcumin on PBMCs; none of the subjects were taking any curcumin supplementation. Flow cytometry and ELISA were used in this study. Curcumin (1 μM, for 72 hours) treatment reduced the frequency of Th17 cells and the levels of related cytokines (IL-6, and IL-17) in women with GDM. Results: The percentage of Th17 cells decreased after treatment with curcumin relative to untreated cells in the GDM group (p = 0.04). Curcumin reduced the IL-17A level in the GDM group (p = 0.01). Curcumin treatment reduced the IL-6 level only in the GDM group (p = 0.02). In the presence of curcumin, the IL-10 level in the supernatants of cell culture was significantly higher in the GDM group compared to the negative control (p = 0.0008). Conclusions: The findings of the present study showed that curcumin modulated the immune responses via balancing of Treg/Th17 in women with GDM. Curcumin increased the level of IL-10, an anti-inflammatory cytokine, whereas it decreased the level of IL-6, which is related to the differentiation of Th17 cells. Curcumin treatment decreased the expression of IL-17A, the main secretory cytokine of Th17 cells. In conclusion, curcumin may act as an immunomodulator component in GDM by balancing the Th17/Treg axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.